ELCC 2016 | ASCEND-1 and ASCEND-2: Ceritinib for ALK-rearranged NSCLC and baseline brain metastases

Giorgio Scagliotti

At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 13–16 April 2016, Giorgio Scagliotti, MD, PhD, from the University of Turin, Turin, Italy, discusses results from ASCEND-1 and ASCEND-2, two non-randomized phase 1/2 multicenter, open-label, single-arm trials evaluating the efficacy of ceritinib, a second-generation anaplastic lymphoma kinase (ALK) inhibitor, in patients with pretreated, ALK-rearranged non-small cell lung cancer (NSCLC) and baseline brain metastases.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter